Rafael Holdings (RFL) EBIT Margin (2017 - 2026)
Rafael Holdings' (RFL) quarterly EBIT Margin came in at 3837.99% in Q2 2026, down 220456.0% year-over-year from N/an in Q2 2025, and down 21.69% quarter-over-quarter from 3154.03% in Q1 2026.
Powered by 
Analysis
Rafael Holdings (RFL) EBIT Margin (2017 - 2026) Analysis & Trends
Rafael Holdings (RFL) has reported EBIT Margin for 10 consecutive years, with 3837.99% the latest figure, recorded in Q2 2026.
- On a quarterly basis, EBIT Margin fell 220456.0% year-over-year to 3837.99% in Q2 2026; TTM through Apr 2026 was 3717.24%, a 95208.0% decrease from a year earlier, with the FY2025 full-year figure at 3179.83%, up 1293116.0% from the prior year.
- EBIT Margin was 3837.99% for Q2 2026 at Rafael Holdings, down from 3154.03% in the prior quarter.
- Over five years, EBIT Margin peaked at 1633.43% in Q2 2025 and troughed at 27726.49% in Q2 2024.
- A 5-year average of 5740.43% and a median of 4032.56% in 2025 frame the typical range for EBIT Margin.
- Across the five-year window, EBIT Margin tumbled 2345747 bps in 2024 and jumped 2609306 bps in 2025, its largest moves.
- Over 5 years, EBIT Margin stood at 7345.71% in 2022, then soared by 50 bps to 3644.12% in 2023, then climbed by 18 bps to 3003.12% in 2024, then tumbled by 41 bps to 4225.42% in 2025, then increased by 9 bps to 3837.99% in 2026.
- The last three EBIT Margin figures came in at 3837.99% (Q2 2026), 3154.03% (Q1 2026), and 4225.42% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -23.56% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -0.36% |
| 10 | Rafael Holdings | 133.65 Mn | 139.07 Mn | 171,000.00 | -3,837.99% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | -3,837.99% |
| Jan 31, 2026 | -3,154.03% |
| Oct 31, 2025 | -4,225.42% |
| Jul 31, 2025 | -3,646.57% |
| Apr 30, 2025 | -1,633.43% |
| Jan 31, 2025 | -8,622.08% |
| Oct 31, 2024 | -3,003.13% |
| Jul 31, 2024 | -2,330.30% |
| Apr 30, 2024 | -27,726.49% |
| Jan 31, 2024 | -4,622.06% |
| Oct 31, 2023 | -3,644.12% |
| Jul 31, 2023 | -3,839.71% |
| Apr 30, 2023 | -4,269.01% |
| Jan 31, 2023 | -6,084.29% |
| Oct 31, 2022 | -7,345.71% |
| Jul 31, 2022 | -7,011.59% |
| Apr 30, 2022 | -6,171.05% |
| Jan 31, 2022 | -2,160.81% |
| Oct 31, 2021 | -25,936.13% |
| Jul 31, 2021 | 518.73% |